1.Degranulation of human eosinophils induced by Paragonimus westermani-secreted protease.
Myeong Heon SHIN ; Young Bae CHUNG ; Hirohito KITA
The Korean Journal of Parasitology 2005;43(1):33-37
Eosinophil degranulation is considered to be a key effector function for the killing of helminthic worms and tissue inflammation at worm-infected lesion sites. However, relatively little data are available with regard to eosinophil response after stimulation with worm-secreted products which contain a large quantity of cysteine proteases. In this study, we attempted to determine whether the degranulation of human eosinophils could be induced by the direct stimulation of the excretory-secretory products (ESP) of Paragonimus westermani, which causes pulmonary paragonimiasis in human beings. Incubation of eosinophils for 3 hr with Paragonimus-secreted products resulted in marked degranulation, as evidenced by the release of eosinophil-derived neurotoxin (EDN) in the culture supernatants. Moreover, superoxide anion was produced by eosinophils after stimulation of the ESP. The ESP-induced EDN release was found to be significantly inhibited when the ESP was pretreated with protease inhibitor cocktail or the cysteine protease inhibitor, E-64. These findings suggest that human eosinophils become degranulated in response to P. westermani-secreted proteases, which may contribute to in vivo tissue inflammation around the worms.
Animals
;
*Cell Degranulation
;
Cysteine Endopeptidases/metabolism/*physiology
;
Eosinophil-Derived Neurotoxin/metabolism
;
Eosinophils/*physiology
;
Humans
;
Paragonimus westermani/*enzymology
;
Research Support, Non-U.S. Gov't
;
Superoxides/metabolism
;
Time Factors
2.The Levels of MDM2 Protein Are Decreased by a Proteasome-Mediated Proteolysis Prior to Caspase-3-Dependent pRb and PARP Cleavages.
Jae We CHO ; Jong Chun PARK ; Je Chul LEE ; Taeg Kyu KWON ; Jong Wook PARK ; Won Ki BAEK ; Seong Il SUH ; Min Ho SUH
Journal of Korean Medical Science 2001;16(2):135-139
MDM2 is a substrate of caspase-3 in p53-mediated apoptosis. In addition, MDM2 mediates its own ubiquitination in a RING finger-dependent manner. Thus, we investigated whether MDM2 is degraded through a ubiquitin-dependent proteasome pathway in the absence of p53. When HL-60 cells, p53 null, were treated with etoposide, MDM2 was markedly decreased prior to caspase-3-dependent retinoblastoma tumor suppressor protein (pRb) and poly (ADP- ribose) polymerase (PARP) cleavages. Moreover, down-regulation of MDM2 level was not coupled with its mRNA down-regulation. However, the level of MDM2 was partially restored by proteasome inhibitors such as LLnL and lactacystin, even in the presence of etoposide. Our results suggest that, in the p53 null status, MDM2 protein level is decreased by proteasome-mediated proteolysis prior to caspase-3-dependent PARP and pRb cleavages.
Antineoplastic Agents, Phytogenic/pharmacology
;
Apoptosis/drug effects/physiology
;
Caspases/*metabolism
;
Cysteine Endopeptidases/*metabolism
;
Down-Regulation (Physiology)/physiology
;
Etoposide/pharmacology
;
HL-60 Cells
;
Human
;
Multienzyme Complexes/*metabolism
;
NAD+ ADP-Ribosyltransferase/*metabolism
;
Proto-Oncogene Proteins/*metabolism
;
Retinoblastoma Protein/*metabolism